drug · small molecule
camlipixant
Phase 3updated 3mo agoby $GSK GSK plc🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 2 investigational indications.
targets
P2X purinoceptor 3
all catalysts(0)
nothing on the calendar yet
Trials studying camlipixant
- phase1A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation Prototypes
- phase2A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
- phase1A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
- phase1Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant
- phase1A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants
- phase1Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
News(7)
- GSK shares rise as $2.5B cost-cutting plan unveiledAs GSK records $2.4 billion in impairment charges for the second quarter, the U.K. pharma has announced a sweeping restructure designed to save about the same amount of money over the next few years.biospace · 17d ago
- GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyardGSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any…fiercebiotech · 17d ago
- GSK shelves cough drug acquired in $2B dealMixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.biopharma_dive · 28d ago
- STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and moreThe number of active medication shortages in the U.S. rose to 227 in the second quarter of 2026stat · 28d ago
- GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 failCamlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, “is unlikely to transform patient care,” the pharma said.biospace · 28d ago
- GSK drops Phase 3 chronic cough drug in a blow to $2B Bellus Health buyoutIn a major stumble for GSK’s $2 billion acquisition of Bellus Health, the UK pharma said Friday it is ending development of camlipixant in refractory chronic cough (RCC) after the drug ...endpoints · 28d ago
- GSK axes key cough drug candidate after phase 3 data end blockbuster hopesGSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the dru…fiercebiotech · 28d ago
Data sources
last refreshed 25m ago
Found something off?
comments(0)
5-min edit window · permanent after that